Categories: Agency News

Medicamen Organics Limited Reports Robust Growth in FY25: Revenue Up 51%, PAT Doubles in H2

Medicamen Organics Limited has announced impressive financial results for FY25, showcasing strong performance across key metrics. The company reported a 51% year-on-year surge in revenue from operations, reaching ₹3,818.77 lakhs. Profit After Tax (PAT) witnessed a remarkable 101% growth in the second half of the fiscal year, while the company’s net worth nearly doubled to ₹3,048.07 lakhs, reflecting solid financial health and consistent operational efficiency.

Highlights:

  • Revenue increased due to a significant export presence in African, CIS, and Southeast Asian countries, being registered in 13 countries.
  • Medicamen Organics Limited has identified significant market potential in:
  • Rising consumer preference for natural, science-backed, and ethically produced beauty products Increasing demand across Tier I and II cities for gender-neutral and inclusive personal care
  • The convergence of beauty, wellness, and lifestyle, offering cross-category synergies
  • Global footprint and a strategic focus on expanding their international market presence.
  • Manufacturing a wide range of pharmaceutical dosage forms including tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.
  • Strong relationships with customers and repeat orders. A loyal customer base and recurring business contribute to consistent and growing revenue streams.

Reflecting on the company’s FY25 performance, Mr. Bal Kishan Gupta, Chairman and Managing Director of Medicamen Organics Limited, stated: We are pleased to announce our formal entry into the cosmetics and personal care industry, through our subsidiary Grande Etiole Pharmaceuticals Limited, marking a significant milestone in its long-term growth and our diversification strategy. Our product portfolio consists of 84 products. We operate under different brand names across the globe. Our business is diversified in terms of geographies and therapeutic areas within the pharmaceutical industry. In terms of geographical diversity, we have marked our presence in India and we have registrations for manufacturing products as approved in international markets in countries like Congo, Benin, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan, Kenya. Our diversified revenue base enables us to mitigate the risk of income concentration by spreading revenue across multiple sources and opens opportunities to new prospects of growth.”

admin

Published by
admin

Recent Posts

PhysicsWallah(PW) and IDP Sign MoU to support global education aspirations of students with IELTS support

India| October 16, 2025: For numerous students, the dream of studying abroad often begins with a…

6 months ago

XLRI Jamshedpur Hosts FULCRUM 5.0: A Conclave of Innovation, AI, and Talent in Consulting

Jamshedpur, October 16, 2025 – On October 11th, XLRI Jamshedpur once again became the epicenter…

6 months ago

Bengaluru Torpedoes Outlast Calicut Heroes in PVL Nail-Biter

Bengaluru Torpedoes outlasted the Calicut Heroes 20-18, 20-18, 7-15, 11-15, 15-12 in a five-set thriller…

6 months ago

Malla Reddy Group of Institutions Announces India’s Largest Digital Collaboration with Google — “Digital Campus on Google Cloud”

Hyderabad, October 16, 2025: In a first-of-its-kind initiative in Telangana, Malla Reddy Group of Institutions…

6 months ago

Hyderabad witnessed business leaders, educators, and women entrepreneurs at one stage at the much-anticipated India Conclave 2025

India Conclave 2025 , organized by Global Triumph Foundation and The Business Ascent, in association with…

6 months ago

Celebrate Diwali with Words, Top 10 Books of the Year by The Rise Insight

Celebrate the spirit of Diwali with the magic of literature! The Rise Insight proudly presents…

6 months ago